Skip to content

Trial Summary

A Phase 3 Multicenter, Randomized, Open Label, active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of previously treated Locally Advanced and unresectable or Metastatic NSCLC Subjects with KRAS p.G12C Mutation

Acronym:

AMG 510 NSCLC

ACTRN/NCT /ethics:

 

Scientific title:

A Phase 3 Multicenter, Randomized, Open Label, active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of previously treated Locally Advanced and unresectable or Metastatic NSCLC Subjects with KRAS p.G12C Mutation

Trial & Patient Characteristics

Cancer TypeLung
Trial TypeTreatment
PhasePhase III
Age Range18+ years
SexBoth
Tumour StreamNSCLC
Cancer StageLocally Recurrent or Locally Advanced, Metastatic or Widespread
Anticipated Start Date-
Anticipated End Date-

Participating Hospitals

HospitalThe Queen Elizabeth Hospital
Clinical Trial CoordinatorPamela Cooper
Emailpamela.cooper@sa.gov.au
Phone08 8222 6410
Principal InvestigatorDr Rachel Roberts-Thomson
Recruitment StatusNot Yet Recruiting